We are delighted to announce a new Dalton Transactions themed issue to be published in 2017:
Frontiers in Radionuclide Imaging and Therapy, “A chemical journey from naturally radioactive elements to targeted theranostic agents” Guest Editors: Professors Angela Casini (Cardiff University), João D. G. Correia (Universidade de Lisboa) and Chris Orvig (University of British Columbia). Deadline: 19th May 2017
Does your research fit into this subject area? If so, we would welcome your contribution. For further details on issue scope and on how to submit, see below:
How to submit
All types of manuscript – communications, full papers, frontiers and perspectives, will be considered for publication. The manuscript should be prepared according to our article guidelines and submitted via our online system.
All manuscripts will be subject to normal peer review and inclusion in the themed issue will be at the discretion of the Guest Editors. Please indicate in your submission the themed issue you would like to be considered for.
Issue scope
This special issue of Dalton Transactions will highlight emerging trends in the use of radionuclides, namely radiometals, for molecular imaging and systemic radiotherapy. It intends to cover all aspects of the use of radionuclides in biomedical/clinical applications, including:
- Updates on the chemistry of d- (e.g. Tc and Re) and f-elements, namely actinides and lanthanides (e.g. Lu and Ho), and their applications in molecular imaging and targeted radionuclide therapy. Metal-based complexes such as those with Ru, Ir or Au may also be included as targeted chemical probes for imaging in biological systems (e.g. cells).
- Multimodal imaging agents with at least one modality being radioactive (e.g. PET- or SPECT-MRI probes; Pet- or SPECT- optical imaging, etc.).
- Radiometal-containing nanoparticles for application in cancer theranostics; image-guided drug delivery in vivo.
- Production and application of alpha emitters (e.g. 212Pb, 213Bi, 223Ra or 211At); new trends and applications.
- Isotopes that are only beginning to become available (by generators, rather than made in cyclotrons or nuclear reactors), such as 68Ga or 213Bi (for alpha therapy).
- Use of “new” or “so far neglected” radioisotopes of the f elements (Lanthanides) for medicinal applications.
Considering the multidisciplinary nature of the topics mentioned, contributions from frontier subjects are welcome. As regards the clinical applications of the above mentioned molecular compounds and nanoparticles, translational aspects should also be addressed in this special issue in addition to chemical design. Thus, contributions related to pharmacological and clinical studies are also welcome.
Interested in submitting a paper? Please contact us (Dalton-RSC@rsc.org) for more information.
